echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Lilly invests 500 million US dollars to help the research and development of Alzheimer's disease drugs of AstraZeneca

    Lilly invests 500 million US dollars to help the research and development of Alzheimer's disease drugs of AstraZeneca

    • Last Update: 2014-09-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: AstraZeneca and Lilly announced recently that they have reached strategic cooperation to develop Alzheimer's disease (AD) drug azd3293, which is an oral β - amyloid precursor protein lyase (bace or β - secretase) inhibitor for early treatment of Alzheimer's disease Azd3293 has been shown to significantly and dose dependently reduce the level of β - amyloid protein in cerebrospinal fluid of Alzheimer's patients and healthy volunteers in phase I study AstraZeneca believes that although the success rate of research and development of azd3293 is only 9%, once listed, the annual sales will exceed 5 billion US dollars According to the terms of the agreement, Lilly will pay AstraZeneca up to $500 million in development and regulatory milestones, and the first $50 million is expected to be paid in the first half of 2015 The two sides will share equally the R & D and commercialization costs of azd3293, as well as the global net income of the drug Lilly will lead clinical trials and work with scientists at the AstraZeneca neuroscience innovation unit, which is responsible for the production of azd3293 AstraZeneca and Lilly plan to rapidly promote azd3293 to phase II / III clinical, to investigate the efficacy and safety of azd3293 for early Alzheimer's disease At present, there are about 35 million people suffering from Alzheimer's syndrome in different degrees in the world, and the cost of Alzheimer's treatment will rise from 200 billion dollars in 2012 to 1.1 trillion dollars in 2050 Among the top 10 causes of death in the United States, Alzheimer's disease is the only disease that can neither be cured nor prevented or slowed down Between 2000 and 2008, breast cancer, heart disease, stroke and AIDS fell by about 3-29%, but the number of Alzheimer's patients increased by 66% At present, there are only five drugs approved for the symptoms of Alzheimer's disease on the market, and no drug can reverse the disease process The huge drug market demand makes pharmaceutical companies continue to develop new drugs, but the research and development of Alzheimer's drugs is very difficult Since mid-2012, six Alzheimer's drugs have entered phase II or phase III of clinical trials Avagacetat, a γ secretase inhibitor of Bristol Myers Squibb, and Baxter's immunoglobulin gamma gard failed to achieve significant efficacy in the treatment of Alzheimer's disease, and the trial was declared unsuccessful in November 2012 and may 2013, respectively Bapineuzumab, a monoclonal antibody of Johnson and Pfizer, and solanezumab, a monoclonal antibody of Lilly, both failed in phase III clinical trials The R & D investment of these two drugs exceeded 1 billion US dollars, which was a very heavy blow in the field of ad new drug R & D Previously, the American pharmaceutical research and Manufacturers Association (Pharma) made statistics on the research and development of Alzheimer's disease drugs from 1998 to 2011 The data shows that in the past 13 years, pharmaceutical companies have cancelled or terminated 101 new drug development, only three drugs have been listed, and the success failure ratio of research and development is only 1:34, and the three new drugs that have been listed are only limited to the symptomatic treatment of Alzheimer's disease Currently, Merck & Co is the leader in the field of BACE inhibitors, and the first phase III clinical data of mk-8931 is expected to be obtained around 2017 Sales of the drug are expected to reach $100 million in 2018 and $200 million in 2019 Whether AstraZeneca's new drug can stand out from the "crisis" remains to be seen (this article is edited and sorted out according to the articles on biological exploration, biological Valley, etc.)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.